The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
|Slideshows|November 14, 2016
Interesting Neuro: Alzheimer Updates & PFO Device
Author(s)Samantha J. Peterson
November news includes potential Alzheimer treatments, FDA approval of a device to prevent recurrent stroke, & a newly typified headache disorder.
Advertisement
We present a selection of interesting neurology articles for the month of November in the following slides. See the slide legends for links to the article summaries.
Advertisement
Related to this article
Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James F. Sumowski, PhD. [LISTEN TIME: 21 minutes]
Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.
The FDA granted fast track designation to FRP-003, an investigational oral botanical drug candidate for Long COVID, ahead of a planned phase 2 trial evaluating fatigue in approximately 220 adults.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
2
FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study
3
New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients
4
Headlining Current Advances and Challenges in Multiple Sclerosis Care
5